Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m Tilmanocept in HIV-associated Kaposi Sarcoma
NCT03157167Phase 1Completed
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Dec 2017
- Primary completion
- Nov 2019
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of technetium tc 99m tilmanocept in Kaposi sarcoma (KS) (3 arms), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoint: Safety of Escalating Doses of Tc 99m Tilmanocept at 10 days. Started Dec 2017; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT03157167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157167.